|
|
||||||||
Departments of Pharmacology and Pediatrics, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
| |
ABSTRACT |
|---|
|
|
|---|
After birth, a dramatic increase in fatty acid oxidation occurs in the heart, which has been attributed to an increase in L-carnitine levels and a switch from the liver (L) to muscle (M) isoform of carnitine palmitoyltransferase (CPT)-1. However, because M-CPT-1 is more sensitive to inhibition by malonyl CoA, a potent endogenous regulator of fatty acid oxidation, a switch to the M-CPT-1 isoform should theoretically decrease fatty acid oxidation. Because of this discrepancy, we assessed the contributions of myocardial L-carnitine content and CPT-1 isoform expression and kinetics to the maturation of fatty acid oxidation in newborn rabbit hearts. Although fatty acid oxidation rates increased between 1 and 14 days after birth, myocardial L-carnitine concentrations did not increase. Changes in the expression of L-CPT-1 or M-CPT-1 mRNA after birth also did not parallel the increase in fatty acid oxidation. The Km of CPT-1 for carnitine and the IC50 for malonyl CoA remained unchanged between 1 and 10 days after birth. However, malonyl CoA levels dramatically decreased, due in part to an increase in malonyl CoA decarboxylase activity. Our data suggest that a decrease in malonyl CoA control of CPT-1 is primarily responsible for the increase in fatty acid oxidation seen in the newborn heart.
carnitine palmitoyltransferase-1; pyruvate dehydrogenase; acetyl CoA carboxylase; glucose oxidation
| |
INTRODUCTION |
|---|
|
|
|---|
FATTY ACID OXIDATION in the newborn heart matures rapidly after birth (16, 29). For example, in 1-day-old rabbit hearts, fatty acid oxidation rates are very low and contribute <10% of the overall ATP production (17). However, by 7 days of age, fatty acid oxidation dramatically increases and becomes the predominant source of energy production. What is responsible for this increase in fatty acid oxidation has not been completely delineated, although an increase in the mitochondrial uptake of fatty acids has been implicated in this process (1, 9, 18). The transport of fatty acids into the mitochondria is primarily controlled at the level of carnitine palmitoyl transferase-1 (CPT-1) (20). CPT-1 is in turn inhibited by malonyl CoA and stimulated by L-carnitine (1, 20, 22, 27, 28). The heart expresses two isoforms of CPT-1, L-CPT-1 and M-CPT-1, with L-CPT-1 being less sensitive to inhibition by malonyl CoA and requiring lower L-carnitine concentrations for maximal stimulation (20, 22, 27, 28).
The dramatic increase in fatty acid oxidation seen in the newborn heart has been attributed to an increase in L-carnitine levels and a switch from the L-CPT-1 isoform to the M-CPT-1 isoform (1). However, because M-CPT-1 is more sensitive to inhibition by malonyl CoA, this switch should actually lead to a decrease in fatty acid oxidation rates, not an increase as previously observed (17, 18, 29). An alternate explanation for the increase in fatty acid oxidation is a decrease in myocardial malonyl CoA levels after birth, resulting in a decrease in malonyl CoA inhibition of CPT-1. Indeed, we have previously shown that after birth, malonyl CoA levels do dramatically decrease in the newborn heart. In 1-day-old rabbit hearts, malonyl CoA levels are very high but decrease dramatically by 7 days after birth (5, 18, 19). These changes in malonyl CoA can be explained by alterations in the control of both malonyl CoA synthesis and degradation (5, 16, 18, 19).
Malonyl CoA is synthesized in the heart by acetyl CoA carboxylase (ACC), the activity of which decreases in the heart after birth (18). ACC is in turn phosphorylated and inactivated by AMP-activated protein kinase (AMPK) (12), the activity and expression of which increases in the heart after birth (19). Malonyl CoA is degraded in the heart by decarboxylation to acetyl CoA by malonyl CoA decarboxylase (MCD) (16). The relative importance of changes in MCD and ACC control of malonyl CoA versus changes in L-carnitine control of CPT-1 or alterations in CPT-1 activity/expression to the increase in fatty acid oxidation in the newborn heart is not clear.
In addition to fatty acid oxidation, glucose oxidation is an important source of energy for the adult heart. In contrast to fatty acid oxidation after birth, rates of glucose oxidation are low in the newborn heart (17) and do not fully mature until after weaning (29). Pyruvate decarboxylation is the key rate-limiting irreversible step in glucose oxidation and is catalyzed by the pyruvate dehydrogenase (PDH) multienzyme complex. Activity of PDH is controlled by kinase-mediated inactivation, responsive to acetyl CoA-to-CoA and NADH-to-NAD+ ratios and phosphatase-mediated activation, which responds to mitochondrial calcium and magnesium concentrations (23). In the adult heart, fatty acids are potent inhibitors of glucose oxidation in the heart, secondary to an increase in the acetyl CoA-to-CoA and NADH-to-NAD+ ratios that result from the oxidation of fatty acids (23). Whether glucose oxidation remains low in the newborn heart due to a delay in the maturation of the enzymes involved in glucose oxidation or to the increase in fatty acid oxidation is not known.
The first aim of this study was to determine the relative contributions of CPT-1 isoform expression, myocardial L-carnitine content, and the kinetics of CPT-1 to the maturation of fatty acid oxidation in the newborn heart. The second aim of this study was to determine whether the low glucose oxidation rates seen in the newborn period are due to a low PDH activity and/or a low capacity for glucose oxidation.
| |
METHODS |
|---|
|
|
|---|
Animals. Newborn New Zealand White rabbits between 1 and 14 days of age were used in this study.
Heart tissue isolation. Newborn rabbits were injected with 60 mg/kg ip pentobarbital sodium. Hearts from anesthetized rabbits were removed and placed in ice-cold Krebs-Henseleit solution. Hearts were then used for either the preparation of mitochondria, cannulated for isolated heart perfusions, or frozen immediately with tongs cooled in liquid N2. Frozen hearts were then ground using a mortar and pestle cooled to the temperature of liquid N2. A sample of frozen heart tissue (~20 mg) was weighed (wet wt) and then dried at 60°C overnight to remove all water (dry wt). The ratio of this sample (dry wt/wet wt) was used to calculate the total dry mass of the heart. Metabolic rates were calculated using the total dry mass of the heart to correct for variations in heart size.
Measurement of heart carnitine content. Samples of frozen tissue were powdered in liquid N2 and then homogenized in 3% perchloric acid, and, after centrifugation, the supernatant was neutralized with KOH. Free carnitine, short-chain acyl carnitine, and long-chain acyl carnitine were extracted from tissue as previously described (13). Carnitine levels were measured using a previously described radioisotopic assay (21).
CPT-1 isoform expression. The expression of M-CPT-1 and L-CPT-1 was measured by RT-PCR of total RNA isolated from neonatal frozen rabbit heart tissue. One microgram of RNA was used in the reactions. A PCR ELISA kit (Roche Diagnostics) was used for this analysis. This system allows for nonradioactive detection of PCR products in a microplate. It is based on the incorporation of digoxygenin (DIG)-labeled dUTP during PCR. These labeled PCR products were then bound to the streptavidin-coated surface of a microplate using biotin-labeled capture probes. The capture probes were designed to hybridize to the internal sequences of the PCR products. The DIG-labeled PCR products were detected with an anti-DIG-alkaline phosphatase conjugate and AttoPhos substrate using a fluorescence microplate reader. The primer sequences and biotin capture probe sequences used in these experiments were as follows: L-CPT-1, primer 1 5'-GTGAAGAAACAACCCCCAGA-3', primer 2 5'-GGAAGCACTTGAGACAAGCC-3', and biotin capture probe 5'-ATCACCTTGTTTGGCCTCAC-3'; and M-CPT-1, primer 1 5'-TGTCATGGCAACAGTTGGTT-3', primer 2 5'-TTGTCCTGGAATTCTTTGGC-3', and biotin capture probe 5'-CCGACAAGGTATGGCTCCTA-3'. The primers were designed from the published sequences for rat M-CPT-1 and L-CPT-1. DNA and protein homology searches were performed with BLAST using GenEMBL or SWISS-PROT databases.
Preparation of mitochondria. Mitochondria were prepared by differential centrifugation using a modified method of Power et al. (24). Briefly, hearts from 1-, 7-, and 10-day-old rabbit hearts were excised and finely minced with scissors in 10 ml of homogenization buffer (0.25 M sucrose, 5 mM Tris · HCl, and 1 mM EGTA; pH 7.4). Two hearts were pooled in the preparation of the mitochondria from 1-day-old hearts due to the low yield. The crude homogenate was centrifuged at 800 g for 10 min at 4°C. The resulting pellet was washed by resuspension in 2 vol of homogenization buffer and was then recentrifuged at 800 g. This step was repeated twice to maximize the yield of mitochondria. The combined supernatants were centrifuged at 6,000 g for 15 min, and the resultant pellet was carefully resuspended in 2 ml of homogenization buffer and centrifuged at 6,000 g for 15 min. The resultant pellet (crude mitochondria) was gently resuspended in 2 ml of homogenization buffer. The crude mitochondrial fraction (0.5 ml) was layered onto 9 ml of 30% Percoll and centrifuged at 50,000 g for 60 min at 4°C. The bottom mitochondrial protein band was collected.
Assay of CPT-1 activity. CPT-1 activity was assayed in the direction of acyl carnitine formation using palmitoyl CoA and carnitine as substrates (8). The final concentrations in the assay were 75 µM palmitoyl CoA, 0.01-1.5 mM carnitine (0.1-20 µCi/µmol L-[14C]carnitine), 4 mM ATP, 4 mM MgCl2, 0.25 mM glutathione, 40 µg/ml rotenone, 2 mM KCN, 15 mM KCl, 1% (wt/vol) BSA, and 105 mM Tris · HCl; pH 7.4. For malonyl CoA inhibition curves, the two substrates of CPT-1, palmitoyl CoA (75 µM) and L-carnitine (0.2 mM), were used at saturating concentrations in the presence of varying concentrations of malonyl CoA ranging from 0 to 1 µM.
MCD activity. MCD activity was measured in rabbit heart tissue using a radiometric assay as described previously (5).
Heart perfusions. Isolated working hearts obtained from 1- and 7-day-old rabbits were used for direct measurement of fatty acid and glucose oxidation as described previously (5, 14, 16, 18). Hearts were perfused with Krebs-Henseleit solution containing 11 mM glucose and 0.4 mM palmitate, prebound to 3% BSA. The perfusate pressure was 60 mmHg, and the time of perfusion was 40 min. Rates of fatty acid and glucose oxidation were measured in separate sets of hearts. Glucose oxidation rates were determined as previously described by trapping and measuring 14CO2 released by the metabolism of [U-14C]glucose in the presence or absence of 0.4 mM palmitate (14). Steady-state rates of palmitate oxidation were measured hearts by quantitatively collecting 14CO2 produced from hearts perfused with [1-14C]palmitate. Metabolic values were normalized for heart mass (dry wt).
PDH activity. PDH activity (both activated and total activity) was measured using a revised protocol (2) based on the radiometric assay described by Constantin-Teodosiu et al. (3).
Statistical analysis. Data are expressed as means ± SE. Comparisons were performed using Student's t-test. Significance was set at P < 0.05. For groups of four or more, ANOVA followed by the Tukey-Kramer multiple-comparisons test was used.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
L-Carnitine content in newborn hearts.
The amounts of free carnitine, long-chain acyl carnitine, and
short-chain acyl carnitine in 1-, 4-, 10-, and 14-day-old rabbits are
shown in Table 1. Myocardial free
carnitine content did not vary dramatically among these four age
groups. An increase in short-chain acyl carnitine and a decrease in
long-chain acyl carnitine was observed during maturation. However,
total carnitine content did not vary dramatically among the four age
groups. The cellular concentrations of carnitine were calculated based
on a cytosolic space of 2 ml/g dry wt in heart muscle and assuming an
equal distribution of carnitine between different subcellular
compartments, as described by Idell-Wenger et al. (13).
The myocardial carnitine concentrations were as follows: 1 day old,
1.83 mM; 4 days old, 1.36 mM; 10 days old, 2.09 mM; and 14 days old,
2.03 mM. Free carnitine concentrations were as follows: 1 day old, 0.6 mM; 4 days old, 0.55 mM; 10 days old, 0.95 mM; and 14 days old, 0.95 mM. These concentrations are all above the Km
for either CPT-1 isoform expressed in the heart, making it unlikely
that carnitine concentration was limiting for CPT-1 activity in the
newborn period.
|
CPT-1 mRNA expression in the newborn heart.
mRNA expression of M-CPT-1 and L-CPT-1 in newborn rabbit hearts is
shown in Fig. 1. The expression of
L-CPT-1 mRNA was increased in the first 3 days after birth but then
returned to 1-day-old levels by day 10 (Fig. 1,
top). In contrast, M-CPT-1 expression was very low in 1-, 3-, and
7-day-old hearts but increased in 10- and 14-day-old hearts (Fig. 1,
bottom). While the expression pattern of mRNA of the two
isoforms of CPT-1 did show changes in the developing rabbit heart, it
is unlikely a switch in CPT-1 from the L-CPT-1 to M-CPT-1 isoform can
explain the increase in fatty acid oxidation observed during this
period. The maturation of fatty acid oxidation in the newborn heart
occurs between 1 and 7 days (from 22.6 ± 5.6 nmol · g dry
wt
1 · min
1 in
1-day-old hearts to 299 ± 46 nmol · g dry
wt
1 · min
1 in
7-day-old hearts). This increase in fatty acid oxidation precedes the
increase in M-CPT-1 expression we observed in these hearts.
|
Kinetics of CPT-1 in newborn rabbit heart mitochondria.
The effects of various L-carnitine concentrations on CPT-1
activity in 1-, 7-, and 10-day-old rabbit hearts is shown in Fig. 2. In heart mitochondria obtained from
all three age groups, increasing L-carnitine concentration
resulted in an increase in CPT-1 activity. In 1- and 7-day-old hearts,
the Vmax for CPT-1 was similar despite a 10-fold
increase in fatty acid oxidation during this period. However, in
10-day-old hearts, CPT-1 activity at higher L-carnitine concentrations was significantly greater than rates in 1- and 7-day-old
hearts. This may reflect the increased expression of M-CPT-1 observed
in these hearts compared with 1-day-old hearts (Fig. 1,
bottom).
|
Malonyl CoA inhibition of CPT-1 in rabbit heart mitochondria.
We also determined whether changes in the sensitivity of CPT-1 to
inhibition by malonyl CoA occur in the newborn heart. Malonyl CoA
inhibition of CPT-1 activity was measured in mitochondria obtained from
1- and 10-day-old hearts (Fig. 3). In
these experiments, mitochondria were exposed to 200 µM
L-carnitine. Similar to the findings shown in Fig. 2, CPT-1
activity in the absence of malonyl CoA was higher in mitochondria from
10-day-old hearts compared with 1-day-old hearts. The addition of
malonyl CoA resulted in a marked inhibition of CPT-1 activity
(~95%). Despite this marked inhibition by malonyl CoA, there was no
significant difference in the sensitivity of CPT-1 to malonyl CoA
inhibition between 1- and 10-day-old hearts. The IC50
values for malonyl CoA were 4 and 5 nM in 1- and 10-day-old rabbit
hearts, respectively.
|
Malonyl CoA degradation in the newborn heart.
We have previously demonstrated that acetyl CoA carboxylase is the key
source of malonyl CoA synthesis in the heart (25) and that
the decrease in malonyl CoA seen in the newborn heart is accompanied by
a decrease in ACC activity (18). Because MCD is the key
mechanism by which malonyl CoA is degraded in the heart (5, 6,
11), we measured MCD activity changes in newborn rabbit hearts
of different ages. As shown in Fig. 4,
the activity of MCD increased in the heart in an age-dependent manner.
This increase in MCD activity was almost maximally increased in
7-day-old hearts, a time period in which malonyl CoA levels
dramatically decrease (18) and fatty acid oxidation rates
dramatically increase (17). This suggests that a drop in
malonyl CoA and a decrease in malonyl CoA inhibition of CPT-1 may be
one of the key mechanisms responsible for the maturation of fatty acid
oxidation after birth.
|
|
Fatty acid control of glucose oxidation in the newborn heart.
Whereas fatty acid oxidation increases dramatically after birth
(probably due to a decrease in malonyl CoA levels), glucose oxidation
(the other main source of acetyl CoA for the tricarboxylic acid cycle)
does not increase during this period (17). Whether this is
due to an increase in fatty acid inhibition of glucose oxidation or due
to a delayed maturation of the enzymes controlling glucose oxidation is
not clear. We therefore determined what happens to the activity of
myocardial PDH, the rate-limiting enzyme for glucose oxidation, in the
newborn period. We measured both the active phosphorylated form of PDH
as well as total PDH activity (Fig. 6). A
progressive age-dependent increase in active PDH and total PDH was
observed between 1-, 7-, and 10-day-old hearts, suggesting that the
capacity for glucose oxidation increases in the newborn period.
|
|
| |
ACKNOWLEDGEMENTS |
|---|
This work was funded by a grant from the Heart and Stroke Foundation of Alberta and Canadian Institutes for Health Research. F. M. Campbell is an Alberta Heritage Foundation for Medical Research postdoctoral fellow. J. R. B. Dyck is an Alberta Heritage Foundation for Medical Research Scholar. G. D. Lopaschuk is an Alberta Heritage Foundation for Medical Research Medical Scientist.
| |
FOOTNOTES |
|---|
* A. O. Besikci and F. M. Campbell contributed equally to this work.
Address for reprint requests and other correspondence: G. D. Lopaschuk, 423 Heritage Medical Research Center, Univ. of Alberta, Edmonton, Alberta, Canada T6G 2S2 (E-mail: gary.lopaschuk{at}ualberta.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published September 5, 2002;10.1152/ajpheart.00461.2002
Received 18 June 2002; accepted in final form 30 August 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Brown, NF,
Weis BC,
Husti JE,
Foster DW,
and
McGarry JD.
Mitochondrial carnitine palmitoyltransferase I isoform switching in the developing rat heart.
J Biol Chem
270:
8952-8957,
1995
2.
Collins-Nakai, RL,
Noseworthy D,
and
Lopaschuk GD.
Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism.
Am J Physiol Heart Circ Physiol
267:
H1862-H1871,
1994
3.
Constantin-Teodosiu, D,
Cederblad G,
and
Hultman E.
A sensitive radioisotopic assay of pyruvate dehydrogenase complex in human muscle tissue.
Anal Biochem
198:
347-351,
1991[Web of Science][Medline].
4.
Cook, GA,
Edwards TL,
Jansen MS,
Bahouth SW,
Wilcox HG,
and
Park EA.
Differential regulation of carnitine palmitoyltransferase-I gene isoforms (CPT-I alpha and CPT-I beta) in the rat heart.
J Mol Cell Cardiol
33:
317-329,
2001[Web of Science][Medline].
5.
Dyck, JRB,
Barr AJ,
Barr R,
Kolattukudy PE,
and
Lopaschuk GD.
Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation.
Am J Physiol Heart Circ Physiol
275:
H2122-H2129,
1998
6.
Dyck, JRB,
Berthiaume LG,
Thomas PD,
Kantor PF,
Barr AJ,
Barr R,
Singh D,
Hopkins TA,
Voilley N,
Prentki M,
and
Lopaschuk GD.
Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism.
Biochem J
350:
599-608,
2000[Medline].
7.
Dyck, JRB,
Kudo N,
Barr AJ,
Davies SP,
Hardie DG,
and
Lopaschuk GD.
Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase.
Eur J Biochem
262:
184-190,
1999[Web of Science][Medline].
8.
Esser, V,
Britton C, H,
Weis BC,
Foster DW,
and
McGarry JD.
Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase. I. Direct evidence that a single polypeptide is involved in inhibitor interaction and catalytic function.
J Biol Chem
268:
5817-5822,
1993
9.
Girard, J,
Ferré P,
Pégorier JP,
and
Duée PH.
Adaptations of glucose and fatty acid metabolism during perinatal period and suckling-weaning transition.
Physiol Rev
72:
507-562,
1992
10.
Habinowski, SA,
Hirshman M,
Sakamoto K,
Kemp BE,
Gould SJ,
Goodyear LJ,
and
Witters LA.
Malonyl-CoA decarboxylase is not a substrate of AMP-activated protein kinase in rat fast-twitch skeletal muscle or an islet cell line.
Arch Biochem Biophys
396:
71-79,
2001[Web of Science][Medline].
11.
Hamilton, C,
and
Saggerson ED.
Malonyl-CoA metabolism in cardiac myocytes.
Biochem J
350:
61-67,
2000[Web of Science][Medline].
12.
Hardie, DG.
Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase.
Biochim Biophys Acta
1301:
231-238,
1992.
13.
Idell-Wenger, JA,
Grotyohann LW,
and
Neely JR.
Coenzyme A and carnitine distribution in normal and ischemic hearts.
J Biol Chem
253:
4310-4318,
1978
14.
Itoi, T,
and
Lopaschuk GD.
Calcium improves mechanical function and carbohydrate metabolism following ischemia in isolated bi-ventricular working hearts from immature rabbits.
J Mol Cell Cardiol
28:
1501-1514,
1996[Web of Science][Medline].
15.
Kantor, PF,
Robertson MA,
Coe JY,
and
Lopaschuk GD.
Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism.
J Am Coll Cardiol
33:
1724-1734,
1999
16.
Lopaschuk, GD,
Belke DD,
Gamble J,
Itoi T,
and
Schonekess BO.
Regulation of fatty acid oxidation in the mammalian heart in health and disease.
Biochim Biophys Acta
1213:
263-276,
1994[Medline].
17.
Lopaschuk, GD,
and
Spafford MA.
Energy substrate utilization by isolated working hearts from newborn rabbits.
Am J Physiol Heart Circ Physiol
258:
H1274-H1280,
1990
18.
Lopaschuk, GD,
Witters LA,
Itoi T,
Barr R,
and
Barr AJ.
Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart.
J Biol Chem
269:
25871-25878,
1994
19.
Makinde, AO,
Gamble J,
and
Lopaschuk GD.
Upregulation of 5'-AMP-activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit.
Circ Res
80:
482-489,
1997
20.
McGarry, JD,
and
Foster DW.
Regulation of hepatic fatty acid oxidation and ketone body production.
Annu Rev Biochem
49:
395-420,
1980[Web of Science][Medline].
21.
McGarry, JD,
and
Foster DW.
Free and esterified carnitine: radiometric method.
In: Methods of Enzyme Analysis, edited by Bergmeyer HU.. Weinheim, Germany: Academic, 1985, p. 474-481.
22.
McGarry, JD,
Mills SE,
Long CS,
and
Foster DW.
Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat.
Biochem J
214:
21-28,
1983[Web of Science][Medline].
23.
Patel, MS,
and
Roche TE.
Molecular biology and biochemistry of pyruvate dehydrogenase complexes.
FASEB J
4:
3224-3233,
1990[Abstract].
24.
Power, GW,
Yaqoob P,
Harvey DJ,
Newsholme EA,
and
Calder PC.
The effect of dietary lipid manipulation on hepatic mitochondrial phospholipid fatty acid composition and carnitine palmitoyltransferase I activity.
Biochem Mol Biol Int
34:
671-684,
1994[Web of Science][Medline].
25.
Saddik, M,
Gamble J,
Witters LA,
and
Lopaschuk GD.
Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart.
J Biol Chem
268:
25836-25845,
1993
26.
Saha, AK,
Schwarsin AJ,
Roduit R,
Masse F,
Kaushik V,
Tornheim K,
Prentki M,
and
Ruderman NB.
Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside.
J Biol Chem
275:
24279-24283,
2000
27.
Weis, BC,
Cowan AT,
Brown N,
Foster DW,
and
McGarry JD.
Use of a selective inhibitor of liver carnitine palmitoyltranferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme.
J Biol Chem
269:
26443-26448,
1994
28.
Weis, BC,
Esser V,
Foster DW,
and
McGarry JD.
Rat heart expresses two forms of mitochondrial carnitine palmitoyltransferase. I. The minor component is identical to the liver enzyme.
J Biol Chem
269:
18712-18715,
1994
29.
Werner, JC,
Sicard RE,
and
Schuler HG.
Palmitate oxidation by isolated working fetal and newborn pig hearts.
Am J Physiol Endocrinol Metab
256:
E315-E321,
1989
30.
Xia, Y,
Buja LM,
and
McMillin JB.
Change in expression of heart carnitine palmitoyltransferase I isoforms with electrical stimulation of cultured rat neonatal cardiac myocytes.
J Biol Chem
271:
12082-12087,
1996
This article has been cited by other articles:
![]() |
T. D. Scholz and J. L. Segar Cardiac Metabolism in the Fetus and Newborn NeoReviews, March 1, 2008; 9(3): e109 - e118. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Stanley, E. E. Morgan, H. Huang, T. A. McElfresh, J. P. Sterk, I. C. Okere, M. P. Chandler, J. Cheng, J. R. B. Dyck, and G. D. Lopaschuk Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2304 - H2309. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Lavrentyev, D. He, and G. A. Cook Expression of genes participating in regulation of fatty acid and glucose utilization and energy metabolism in developing rat hearts Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2035 - H2042. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |